New Obesity Treatment Injection "RES-010" - A New Strategy to "Rewrite Metabolism" Without Changing Diet

Traditional weight loss drugs, such as GLP-1 receptor agonists, primarily induce weight loss by suppressing appetite. However, the new injectable drug "RES-010," being developed by Italy's Resalis Therapeutics, takes a different approach. It inhibits the microRNA miR-22, which acts as a "metabolic commander," using antisense oligonucleotides to simultaneously rewire fundamental metabolic pathways such as lipid metabolism, mitochondrial activity, and the browning of white fat, aiming to preferentially reduce fat **"without changing the amount of food consumed."** Preclinical results presented at the EASD (European Association for the Study of Diabetes) in Vienna suggested a 15% reduction in fat mass, preservation of lean mass (-1%), and suppression of rebound after discontinuation in obese mice and monkeys. Currently, a Phase 1 trial is underway in the Netherlands (with up to 80 participants, initial dosing in November 2024). While conclusions on efficacy in humans are still forthcoming, there is potential for reducing rebound when combined with GLP-1. Introducing the drug in Japan will require domestic trials and approval processes, which will take several years. It is realistic to position this as an option under medical supervision, avoiding excessive expectations or misconceptions about "losing weight while eating freely."